$GTHP
GUIDED THERAPEUTICS INC Stock $gthp

$gthp Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000147793224001549 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$6.000K	$32.00K	$98.00K
YoY Change	-72.73%		653.85%
Cost Of Revenue	$2.000K	$16.00K	$62.00K
YoY Change	-77.78%	-79.75%	-23.46%
Gross Profit	$4.000K	$16.00K	$36.00K
YoY Change	-69.23%	-120.25%	-152.94%
Gross Profit Margin	66.67%	50.0%	36.73%
Selling, General & Admin	$309.0K	$415.0K	$3.265M
YoY Change	-63.6%	-50.0%	2.42%
% of Gross Profit	7725.0%	2593.75%	9069.44%
Research & Development	$54.00K	$86.00K	$228.0K
YoY Change	671.43%	120.51%	196.1%
% of Gross Profit	1350.0%	537.5%	633.33%
Depreciation & Amortization	$2.000K	-$1.000K	$9.000K
YoY Change	0.0%	-133.33%	125.0%
% of Gross Profit	50.0%	-6.25%	25.0%
Operating Expenses	$363.0K	$501.0K	$3.493M
YoY Change	-57.59%	-42.35%	6.98%
Operating Profit	-$359.0K	-$485.0K	-$3.457M
YoY Change	-57.41%	-48.84%	3.72%
Interest Expense	$64.00K	-$66.00K	-$267.0K
YoY Change	-3.03%	17.86%	-145.88%
% of Operating Profit
Other Income/Expense, Net	-$43.00K	$38.00K	$39.00K
YoY Change	65.38%	245.45%	-103.87%
Pretax Income	-$402.0K	-$386.0K	-$3.489M
YoY Change	-53.74%	-78.64%	-19.63%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$402.0K	-$469.0K	-$3.759M
YoY Change	-53.74%	-74.74%	-13.41%
Net Earnings / Revenue	-6700.0%	-1465.63%	-3835.71%
Basic Earnings Per Share	-$0.01		-$0.07
Diluted Earnings Per Share	-$0.01	-$0.01	-$0.07
COMMON SHARES
Basic Shares Outstanding	55.61M shares	52.10M shares
Diluted Shares Outstanding	54.75K shares		51.13M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$445.0K	$591.0K	$591.0K
YoY Change	-75.78%	-74.45%	-74.45%
Cash & Equivalents	$445.0K	$591.0K	$591.0K
Short-Term Investments
Other Short-Term Assets	$156.0K	$163.0K	$163.0K
YoY Change	28.93%	18.98%	18.98%
Inventory	$632.0K	$632.0K	$632.0K
Prepaid Expenses
Receivables	$7.000K	$7.000K	$7.000K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.240M	$1.393M	$1.393M
YoY Change	-51.37%	-53.63%	-53.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$30.00K	$259.0K	$259.0K
YoY Change	-25.0%	516.67%	-24.93%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$17.00K	$17.00K	$17.00K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$254.0K	$276.0K	$276.0K
YoY Change	-25.73%	-23.76%	-23.76%
TOTAL ASSETS
Total Short-Term Assets	$1.240M	$1.393M	$1.393M
Total Long-Term Assets	$254.0K	$276.0K	$276.0K
Total Assets	$1.494M	$1.669M	$1.669M
YoY Change	-48.34%	-50.42%	-50.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.924M	$2.023M	$2.023M
YoY Change	-12.19%	-7.46%	-9.08%
Accrued Expenses	$780.0K	$833.0K	$833.0K
YoY Change	-15.95%	-33.2%	-23.93%
Deferred Revenue
YoY Change
Short-Term Debt	$1.253M	$1.262M	$1.262M
YoY Change	405.24%	338.19%	338.19%
Long-Term Debt Due	$512.0K	$39.00K	$39.00K
YoY Change		129.41%	-92.51%
Total Short-Term Liabilities	$5.342M	$4.809M	$4.809M
YoY Change	33.45%	-1.23%	-1.23%
LONG-TERM LIABILITIES
Long-Term Debt	$34.00K	$511.0K	$511.0K
YoY Change	-97.76%		-54.74%
Other Long-Term Liabilities	$130.0K	$155.0K	$155.0K
YoY Change	-42.22%	-38.25%	-38.25%
Total Long-Term Liabilities	$164.0K	$666.0K	$666.0K
YoY Change	-90.6%	-51.74%	-51.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.342M	$4.809M	$4.809M
Total Long-Term Liabilities	$164.0K	$666.0K	$666.0K
Total Liabilities	$5.506M	$5.475M	$5.475M
YoY Change	-4.19%	-12.39%	-12.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$151.6M	-$151.1M
YoY Change	2.18%	2.55%
Common Stock	$3.441M	$3.441M
YoY Change	0.09%	0.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$132.0K	$132.0K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	-$4.012M	-$3.806M	-$3.806M
YoY Change
Total Liabilities & Shareholders Equity	$1.494M	$1.669M	$1.669M
YoY Change	-48.34%	-50.42%	-50.42%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$402.0K	-$469.0K	-$3.759M
YoY Change	-53.74%	-74.74%	-13.41%
Depreciation, Depletion And Amortization	$2.000K	-$1.000K	$9.000K
YoY Change	0.0%	-133.33%	125.0%
Cash From Operating Activities	-$100.0K	-$336.0K	-$1.746M
YoY Change	-79.96%	-0.59%	18.13%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change
Cash From Investing Activities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$436.0K
YoY Change			-68.68%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$46.00K	194.0K	24.00K
YoY Change	-300.0%	-561.9%	-99.25%
NET CHANGE
Cash From Operating Activities	-$100.0K	-336.0K	-1.746M
Cash From Investing Activities		0.000	0.000
Cash From Financing Activities	-$46.00K	194.0K	24.00K
Net Change In Cash	-$146.0K	-142.0K	-1.722M
YoY Change	-69.33%	-62.92%	-203.05%
FREE CASH FLOW
Cash From Operating Activities	-$100.0K	-$336.0K	-$1.746M
Capital Expenditures			$0.00
Free Cash Flow			-$1.746M
YoY Change			15.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Inventory Net InventoryNet	632000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3441000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	137000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1393000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	3004000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	227000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	303000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	970000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1247000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	424000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	509000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	91000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	79000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	17000	usd
CY2022Q4	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	57000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	276000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	362000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1991000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4869000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	155000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	246000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-147359000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3366000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	548000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	163000	usd
CY2023Q4	us-gaap	Assets Assets	1669000	usd
CY2022Q4	us-gaap	Assets Assets	3366000	usd
CY2023Q4	gthp	Account Payable Related Parties Current AccountPayableRelatedPartiesCurrent	32000	usd
CY2022Q4	gthp	Account Payable Related Parties Current AccountPayableRelatedPartiesCurrent	39000	usd
CY2023Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	2000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	818000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2186000	usd
CY2023Q4	gthp	Current Portion Of Long Term Debt Related Parties CurrentPortionOfLongTermDebtRelatedParties	39000	usd
CY2022Q4	gthp	Current Portion Of Long Term Debt Related Parties CurrentPortionOfLongTermDebtRelatedParties	504000	usd
CY2023Q4	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	59000	usd
CY2023Q4	gthp	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	0	usd
CY2022Q4	gthp	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	1000	usd
CY2023Q4	gthp	Short Term Convertible Notes Payable Including Nonconvertible Penalty ShortTermConvertibleNotesPayableIncludingNonconvertiblePenalty	1203000	usd
CY2022Q4	gthp	Short Term Convertible Notes Payable Including Nonconvertible Penalty ShortTermConvertibleNotesPayableIncludingNonconvertiblePenalty	230000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4809000	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1046000	usd
CY2023Q4	gthp	Current Portion Of Long Term Debt Related Parties Non Current CurrentPortionOfLongTermDebtRelatedPartiesNonCurrent	511000	usd
CY2022Q4	gthp	Current Portion Of Long Term Debt Related Parties Non Current CurrentPortionOfLongTermDebtRelatedPartiesNonCurrent	83000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1380000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	5475000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6249000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54105000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48596000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3437000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	140983000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	132000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	132000	usd
CY2023Q4	gthp	Stockholders Equity Amresh StockholdersEquityAmresh	-3806000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1669000	usd
CY2022	gthp	Bad Debt Expense BadDebtExpense	23000	usd
CY2023	us-gaap	Depreciation Depreciation	9000	usd
CY2022	us-gaap	Depreciation Depreciation	4000	usd
CY2022	gthp	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	27000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	76000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	68000	usd
CY2023	gthp	Gain From Forgiveness Of Debt GainFromForgivenessOfDebt	196000	usd
CY2022	gthp	Gain From Forgiveness Of Debt GainFromForgivenessOfDebt	186000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	26000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	172000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-16000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	84000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	58000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	103000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	363000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	43000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	122000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-79000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-67000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	172000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1746000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1479000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	436000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	532000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	412000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1392000	usd
CY2023	gthp	Proceeds From Issuances Of Warrants Net Of Costs ProceedsFromIssuancesOfWarrantsNetOfCosts	0	usd
CY2022	gthp	Proceeds From Issuances Of Warrants Net Of Costs ProceedsFromIssuancesOfWarrantsNetOfCosts	1796000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3180000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1722000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1670000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2313000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	643000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2313000	usd
CY2023	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	171000	usd
CY2022	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	631000	usd
CY2023	gthp	Deemed Dividends For Warrant Exchanges DeemedDividendsForWarrantExchanges	99000	usd
CY2022	gthp	Deemed Dividends For Warrant Exchanges DeemedDividendsForWarrantExchanges	0	usd
CY2023	gthp	Settlement Of Interest Through Common Stock Issuance SettlementOfInterestThroughCommonStockIssuance	119000	usd
CY2022	gthp	Settlement Of Interest Through Common Stock Issuance SettlementOfInterestThroughCommonStockIssuance	151000	usd
CY2023	gthp	Settlement Of Dividends Through Common Stock Issuance SettlementOfDividendsThroughCommonStockIssuance	173000	usd
CY2022	gthp	Settlement Of Dividends Through Common Stock Issuance SettlementOfDividendsThroughCommonStockIssuance	730000	usd
CY2023	gthp	Settlement Of Previously Accrued Professional Fees Through Common Stock Issuance SettlementOfPreviouslyAccruedProfessionalFeesThroughCommonStockIssuance	168000	usd
CY2022	gthp	Settlement Of Previously Accrued Professional Fees Through Common Stock Issuance SettlementOfPreviouslyAccruedProfessionalFeesThroughCommonStockIssuance	0	usd
CY2023	gthp	Conversion Of Series D Preferred Shares Into Common Stock ConversionOfSeriesDPreferredSharesIntoCommonStock	0	usd
CY2022	gthp	Conversion Of Series D Preferred Shares Into Common Stock ConversionOfSeriesDPreferredSharesIntoCommonStock	118000	usd
CY2023	gthp	Conversion Of Series E Preferred Shares Into Common Stock ConversionOfSeriesEPreferredSharesIntoCommonStock	5000	usd
CY2022	gthp	Conversion Of Series E Preferred Shares Into Common Stock ConversionOfSeriesEPreferredSharesIntoCommonStock	800000	usd
CY2023	gthp	Conversion Of Series F Preferred Shares Into Common Stock ConversionOfSeriesFPreferredSharesIntoCommonStock	42000	usd
CY2022	gthp	Conversion Of Series F Preferred Shares Into Common Stock ConversionOfSeriesFPreferredSharesIntoCommonStock	308000	usd
CY2023	gthp	Conversion Of Series F2 Preferred Shares Into Common Stock ConversionOfSeriesF2PreferredSharesIntoCommonStock	14000	usd
CY2022	gthp	Conversion Of Series F2 Preferred Shares Into Common Stock ConversionOfSeriesF2PreferredSharesIntoCommonStock	2473000	usd
CY2023	gthp	Directors And Officers Insurance Obtained With Financing DirectorsAndOfficersInsuranceObtainedWithFinancing	129000	usd
CY2022	gthp	Directors And Officers Insurance Obtained With Financing DirectorsAndOfficersInsuranceObtainedWithFinancing	124000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000924515
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	818000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48596000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54105000	shares
CY2020Q4	gthp	Share Outstanding One ShareOutstandingOne	13138282	shares
CY2022Q4	gthp	Common Stock Shares Authorized Shares CommonStockSharesAuthorizedShares	500000000	shares
CY2022Q4	gthp	Common Stocks Shares Outstanding CommonStocksSharesOutstanding	48595715	shares
CY2023Q4	gthp	Common Stocks Shares Outstanding CommonStocksSharesOutstanding	54105101	shares
CY2023	gthp	Weighted Average Remaining Contractual Life Beginning WeightedAverageRemainingContractualLifeBeginning	P7Y5M30D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	109404	usd
CY2023Q4	gthp	Short Term Notes Payable Due To Related Parties ShortTermNotesPayableDueToRelatedParties	0	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	56569	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0	pure
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	0-22179
CY2023	dei	Entity Registrant Name EntityRegistrantName	GUIDED THERAPEUTICS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	58-2029543
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	5835 Peachtree Corners East
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite B
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Peachtree Corners
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30092
CY2023	dei	City Area Code CityAreaCode	770
CY2023	dei	Local Phone Number LocalPhoneNumber	242-8723
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	11477380	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55613449	shares
CY2023	dei	Auditor Firm AuditorFirmId	1195
CY2023	dei	Auditor Name AuditorName	UHY LLP
CY2023	dei	Auditor Location AuditorLocation	Sterling Heights, Michigan
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	591000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2313000	usd
CY2022Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	48000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	5000	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	0	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	666000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	138090000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151118000	usd
CY2022Q4	gthp	Stockholders Equity Amresh StockholdersEquityAmresh	-2883000	usd
CY2023	us-gaap	Revenues Revenues	98000	usd
CY2022	us-gaap	Revenues Revenues	13000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	62000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	81000	usd
CY2023	us-gaap	Gross Profit GrossProfit	36000	usd
CY2022	us-gaap	Gross Profit GrossProfit	-68000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	228000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	77000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	268000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	181000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2997000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3007000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	3493000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	3265000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-3457000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3333000	usd
CY2023	us-gaap	Interest Expense InterestExpense	278000	usd
CY2022	us-gaap	Interest Expense InterestExpense	582000	usd
CY2023	us-gaap	Interest Income Operating InterestIncomeOperating	6000	usd
CY2022	us-gaap	Interest Income Operating InterestIncomeOperating	0	usd
CY2023	gthp	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	5000	usd
CY2022	gthp	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	27000	usd
CY2023	gthp	Gain From Extinguishment Of Debt GainFromExtinguishmentOfDebt	196000	usd
CY2022	gthp	Gain From Extinguishment Of Debt GainFromExtinguishmentOfDebt	-469000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	39000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	16000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-32000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1008000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3489000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4341000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3489000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4341000	usd
CY2023	gthp	Deemed Dividend For Warrant Exchanges DeemedDividendForWarrantExchanges	-99000	usd
CY2022	gthp	Deemed Dividend For Warrant Exchanges DeemedDividendForWarrantExchanges	0	usd
CY2023	us-gaap	Dividends Preferred Stock DividendsPreferredStock	171000	usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	631000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3759000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4972000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2023	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	51131000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	32505000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51131000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32505000	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2883000	usd
CY2023	gthp	Common Stock Warrants Exercised Amount CommonStockWarrantsExercisedAmount	472000	usd
CY2023	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	30000	usd
CY2023	gthp	Issuance Of Common Stock For Payment Of Series E Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividendsAmount	61000	usd
CY2023	gthp	Issuance Of Common Stock For Payment Of Series F Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesFPreferredDividendsAmount	53000	usd
CY2023	gthp	Issuance Of Common Stock For Payment Of Series F2 Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesF2PreferredDividendsAmount	29000	usd
CY2023	gthp	Conversion Of Series E Preferred Stock To Common Stock Amount ConversionOfSeriesEPreferredStockToCommonStockAmount	0	usd
CY2023	gthp	Conversion Of Series F Preferred Stock To Common Stock Amount ConversionOfSeriesFPreferredStockToCommonStockAmount	0	usd
CY2023	gthp	Conversion Of Series F2 Preferred Stock To Common Stock Amount ConversionOfSeriesF2PreferredStockToCommonStockAmount	0	usd
CY2023	gthp	Issuance Of Common Stock For Payment Of Interest Amount IssuanceOfCommonStockForPaymentOfInterestAmount	119000	usd
CY2023	gthp	Settlement Of Previously Accrued Professional Fees Through Common Stock Issuance Amount SettlementOfPreviouslyAccruedProfessionalFeesThroughCommonStockIssuanceAmount	168000	usd
CY2023	gthp	Stockbasedcompensationn Stockbasedcompensationn	1806000	usd
CY2023	gthp	Impact Of Warrant Exchanges ImpactOfWarrantExchanges	0	usd
CY2023	gthp	Accruedpreferreddividends Accruedpreferreddividends	-172000	usd
CY2023	gthp	Net Income Losses NetIncomeLosses	-3489000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-3806000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-5445000	usd
CY2022	gthp	Common Stock Warrants Exercised Amount CommonStockWarrantsExercisedAmount	846000	usd
CY2022	gthp	Issuances Of Common Stock To Investors Amount IssuancesOfCommonStockToInvestorsAmount	1429000	usd
CY2022	gthp	Issuances Of Warrants To Investors IssuancesOfWarrantsToInvestors	1795000	usd
CY2022	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	47000	usd
CY2022	gthp	Issuance Of Common Stock For Payment Of Series E Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividendsAmount	102000	usd
CY2022	gthp	Issuance Of Common Stock For Payment Of Series F Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesFPreferredDividendsAmount	107000	usd
CY2022	gthp	Issuance Of Common Stock For Payment Of Series F2 Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesF2PreferredDividendsAmount	75000	usd
CY2022	gthp	Issuance Of Common Stock For Payment Of Interest Amount IssuanceOfCommonStockForPaymentOfInterestAmount	150000	usd
CY2022	gthp	Issuance Of Common Stock For Series F And Series F2 One Time15 Dividends Amount IssuanceOfCommonStockForSeriesFAndSeriesF2OneTime15DividendsAmount	400000	usd
CY2022	gthp	Conversion Of Series C2 Preferred Stock To Common Stock Amount ConversionOfSeriesC2PreferredStockToCommonStockAmount	0	usd
CY2022	gthp	Conversion Of Series D Preferred Stock To Common Stock Amount ConversionOfSeriesDPreferredStockToCommonStockAmount	0	usd
CY2022	gthp	Conversion Of Series E Preferred Stock To Common Stock Amount ConversionOfSeriesEPreferredStockToCommonStockAmount	0	usd
CY2022	gthp	Conversion Of Series F Preferred Stock To Common Stock Amount ConversionOfSeriesFPreferredStockToCommonStockAmount	0	usd
CY2022	gthp	Conversion Of Series F2 Preferred Stock To Common Stock Amount ConversionOfSeriesF2PreferredStockToCommonStockAmount	0	usd
CY2022	gthp	Stockbasedcompensationn Stockbasedcompensationn	176000	usd
CY2022	gthp	Issuances Of Warrants To Consultants IssuancesOfWarrantsToConsultants	1204000	usd
CY2022	gthp	Impact Of Auctus Exchange Amount ImpactOfAuctusExchangeAmount	1203000	usd
CY2022	gthp	Accruedpreferreddividends Accruedpreferreddividends	-631000	usd
CY2022	gthp	Net Income Losses NetIncomeLosses	-4341000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2883000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-3489000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-4341000	usd
CY2023	gthp	Bad Debt Expense BadDebtExpense	2000	usd
CY2023	gthp	Inventory Reserve InventoryReserve	0	usd
CY2022	gthp	Inventory Reserve InventoryReserve	81000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	130000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	143000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1806000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1381000	usd
CY2023	gthp	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	5000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	655000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-85000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	540000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	591000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	107000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	149000	usd
CY2023	gthp	Conversion Of Series C2 Preferred Shares Into Common Stock ConversionOfSeriesC2PreferredSharesIntoCommonStock	0	usd
CY2022	gthp	Conversion Of Series C2 Preferred Shares Into Common Stock ConversionOfSeriesC2PreferredSharesIntoCommonStock	92000	usd
CY2023Q4	gthp	Working Capital WorkingCapital	-3400000	usd
CY2023Q4	gthp	Retained Earning Accumulated Deficit RetainedEarningAccumulatedDeficit	-151100000	usd
CY2023	gthp	Net Loss Preferred Dividend NetLossPreferredDividend	-3800000	usd
CY2023Q4	gthp	Preconfirmations Stockholders Equity PreconfirmationsStockholdersEquity	-3800000	usd
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	436000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for credit losses, inventory valuation and input variables for Black-Scholes and binomial option pricing models. The Company uses the binomial option pricing model for the calculation of the fair value of freestanding warrants with market conditions.
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	The Company maintains cash balances that are insured by the Federal Deposit Insurance Corporation up to certain federal limitations. At times, the Company’s cash balance exceeds these federal limitations. The amount in excess of insured limitations was approximately $156,112 and $2,064,772 as of December 31, 2023 and 2022, respectively.<strong> </strong>
CY2023Q4	gthp	Excessed Amount Of Insured Limitations ExcessedAmountOfInsuredLimitations	156112	usd
CY2022Q4	gthp	Excessed Amount Of Insured Limitations ExcessedAmountOfInsuredLimitations	2064772	usd
CY2022	gthp	Costs Incurred In Filing CostsIncurredInFiling	5400	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1360000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1260000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	46000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	68000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	44000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	38000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	818000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	818000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	632000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	548000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1614000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1792000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1582000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1750000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	177685	usd
CY2023	gthp	Costs Incurred In Filing CostsIncurredInFiling	30500	usd
CY2023Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	401000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	444000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	216000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	285000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	90000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	189000	usd
CY2023Q4	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	27000	usd
CY2022Q4	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	41000	usd
CY2023Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	228000	usd
CY2022Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	231000	usd
CY2023Q4	gthp	Accrued Stock Subscription Payable AccruedStockSubscriptionPayable	0	usd
CY2022Q4	gthp	Accrued Stock Subscription Payable AccruedStockSubscriptionPayable	36000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	8000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	21000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	970000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1247000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	424225	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	509101	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	337315	usd
CY2023Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	7442	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1500	usd
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	6312	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	48172	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	66400000	usd
CY2023	us-gaap	Premiums Percentage Assumed To Net PremiumsPercentageAssumedToNet	0.500	pure
CY2019Q4	gthp	Derivative Liability Bifurcated Conversion Option Actus Loan Amount DerivativeLiabilityBifurcatedConversionOptionActusLoanAmount	326016	usd
CY2022Q4	gthp	Common Stock Shares Issued1 CommonStockSharesIssued1	6711540	shares
CY2022Q4	gthp	Aggregate Shares Of Common Stock AggregateSharesOfCommonStock	6711540	shares
CY2022Q3	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	0.65
CY2022Q4	gthp	Aggregate Purchase Price Of Transaction AggregatePurchasePriceOfTransaction	3355270	usd
CY2023	gthp	Proceeds From Expenses And Fees Received ProceedsFromExpensesAndFeesReceived	3200000	usd
CY2023Q4	gthp	Common Stock Shares Authorized Shares CommonStockSharesAuthorizedShares	500000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	gthp	Common Stocks Shares Issued CommonStocksSharesIssued	54105101	shares
CY2022Q4	gthp	Common Stocks Shares Issued CommonStocksSharesIssued	48595715	shares
CY2021Q4	gthp	Share Outstanding One ShareOutstandingOne	13673583	shares
CY2022	gthp	Common Shares Issued CommonSharesIssued	34922132	shares
CY2022Q4	gthp	Share Outstanding One ShareOutstandingOne	48595715	shares
CY2023	gthp	Common Shares Issued CommonSharesIssued	5509386	shares
CY2023Q4	gthp	Share Outstanding One ShareOutstandingOne	54105101	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	27669634	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.29
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	24223080	shares
CY2022	gthp	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Warrant Issued ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceWarrantIssued	0.54
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	4450866	shares
CY2022	gthp	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceExpired	0.54
CY2022	gthp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exchanged ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExchanged	-8775000	usd
CY2022	gthp	Share Based Compensation Arrangement By Share Based Payment Award Options For Exchange In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForExchangeInPeriodWeightedAverageExercisePrice	0.19
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	3079868	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.17
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	35586980	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.46
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	8782730	shares
CY2023	gthp	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Warrant Issued ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceWarrantIssued	0.22
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	9545200	shares
CY2023	gthp	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceExpired	0.30
CY2023	gthp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exchanged ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExchanged	-3257200	usd
CY2023	gthp	Share Based Compensation Arrangement By Share Based Payment Award Options For Exchange In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForExchangeInPeriodWeightedAverageExercisePrice	0.25
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	2982730	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.15
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	28584580	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.50
CY2023	gthp	Schedule Of Fair Value Warrants Issued Under Black Scholes Option Pricing Model Table Textblock ScheduleOfFairValueWarrantsIssuedUnderBlackScholesOptionPricingModelTableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected term</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2.9 Years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">241.2</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Risk-free interest rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected term</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">3.8 Years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148.4</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Risk-free interest rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.6</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table>
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y10M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.412	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.033	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y9M18D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.484	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.036	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2023Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.10	pure
CY2023Q1	gthp	Vesting Period Description VestingPeriodDescription	fourth of the stock options vested immediately, while the remaining options will vest over a period of 33 months, beginning on May 10, 2023
CY2023Q1	gthp	Vesting Period Description VestingPeriodDescription	One fourth of the stock options vested immediately, while the remaining options will vest over a period of 33 months, beginning on June 7, 2023
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	235980	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	175647	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1500000	shares
CY2021Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.49
CY2022	gthp	Weighted Average Remaining Contractual Life Beginning WeightedAverageRemainingContractualLifeBeginning	P7Y6M
CY2022Q4	gthp	Agrregate Intrensic Value AgrregateIntrensicValue	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1318091	shares
CY2022	gthp	Weighted Average Exercise Price Per Share Exercisable WeightedAverageExercisePricePerShareExercisable	0.49
CY2022	gthp	Weighted Average Remaining Contractual Life Exercisable WeightedAverageRemainingContractualLifeExercisable	P7Y6M
CY2022	gthp	Agrregate Intrensic Value Exercisable AgrregateIntrensicValueExercisable	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1500000	shares
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.49
CY2022	gthp	Weighted Average Remaining Contractual Life Ending WeightedAverageRemainingContractualLifeEnding	P7Y6M
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1025000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.26
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	186364	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2338636	shares
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.41
CY2023	gthp	Weighted Average Remaining Contractual Life Ending WeightedAverageRemainingContractualLifeEnding	P6Y6M
CY2023Q4	gthp	Agrregate Intrensic Value AgrregateIntrensicValue	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1867614	shares
CY2023	gthp	Weighted Average Exercise Price Per Share Exercisable WeightedAverageExercisePricePerShareExercisable	0.44
CY2023	gthp	Weighted Average Remaining Contractual Life Exercisable WeightedAverageRemainingContractualLifeExercisable	P5Y10M24D
CY2023	gthp	Agrregate Intrensic Value Exercisable AgrregateIntrensicValueExercisable	0	usd
CY2023	gthp	Unrecognized Stock Based Compensation Expense UnrecognizedStockBasedCompensationExpense	124251	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y3M
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.26
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	109404	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	227000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	303000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	246000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	325000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	115000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	118000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	50000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	283000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	37000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	246000	usd
CY2023	us-gaap	Finite Lived Intangible Asset Weighted Average Period Before Next Renewal Or Extension FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension	P2Y4M24D
CY2022	us-gaap	Finite Lived Intangible Asset Weighted Average Period Before Next Renewal Or Extension FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension	P3Y4M24D
CY2023	gthp	Weighted Average Discount Rateoperating Lease WeightedAverageDiscountRateoperatingLease	0.114	pure
CY2022	gthp	Weighted Average Discount Rateoperating Lease WeightedAverageDiscountRateoperatingLease	0.114	pure
CY2016Q2	gthp	Royalty Percent RoyaltyPercent	0.20	pure
CY2020Q1	gthp	Warrants Broken Into Four Tranches WarrantsBrokenIntoFourTranches	1250000	shares
CY2020Q1	us-gaap	Share Price SharePrice	0.25
CY2023Q4	gthp	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	2500000	shares
CY2023Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	875000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	787500	shares
CY2023Q4	us-gaap	Share Price SharePrice	0.12
CY2019Q3	gthp	Consideration Received ConsiderationReceived	885144	usd
CY2019Q3	gthp	Escrow Agent Rate Per Share EscrowAgentRatePerShare	1.90
CY2023Q3	us-gaap	Line Of Credit Facility Average Outstanding Amount LineOfCreditFacilityAverageOutstandingAmount	129073	usd
CY2023Q3	us-gaap	Repayments Of Debt RepaymentsOfDebt	12041	usd
CY2023Q3	gthp	Accrued Interest Rate AccruedInterestRate	0.079	pure
CY2022Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2024-05-04
CY2022Q3	us-gaap	Line Of Credit Facility Average Outstanding Amount LineOfCreditFacilityAverageOutstandingAmount	123889	usd
CY2022Q3	us-gaap	Repayments Of Debt RepaymentsOfDebt	11409	usd
CY2022Q3	gthp	Accrued Interest Rate AccruedInterestRate	0.050	pure
CY2023Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-05-04
CY2023Q4	us-gaap	Notes Payable NotesPayable	56569	usd
CY2023Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	59000	usd
CY2022Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	58000	usd
CY2022Q4	gthp	Short Term Notes Payable Due To Related Parties ShortTermNotesPayableDueToRelatedParties	619	usd
CY2019Q4	us-gaap	Convertible Debt ConvertibleDebt	2400000	usd
CY2023Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.24	pure
CY2023	gthp	Convertible Debt Conversion Price Description ConvertibleDebtConversionPriceDescription	variable conversion price was 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date)
CY2019Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.04
CY2019Q4	gthp	Variable Conversion Price VariableConversionPrice	0.15
CY2022Q3	gthp	Early Repayment Of Senior Debt Penalty EarlyRepaymentOfSeniorDebtPenalty	350000	usd
CY2022Q3	gthp	Default Premiums DefaultPremiums	281256	usd
CY2022Q3	gthp	Interest Payable InterestPayable	91555	usd
CY2022Q3	gthp	Amount Reduce After Exchange AmountReduceAfterExchange	710911	usd
CY2022Q3	gthp	Warrant Exchange WarrantExchange	8775000	shares
CY2022Q3	gthp	Debt Instrument Default Penalty Forgiven DebtInstrumentDefaultPenaltyForgiven	225444	usd
CY2023	gthp	Loss On Extinguishment Of Debt LossOnExtinguishmentOfDebt	123039	usd
CY2023Q4	gthp	Senior Unsecured Convertible Debentures SeniorUnsecuredConvertibleDebentures	1130000	usd
CY2022Q4	gthp	Senior Unsecured Convertible Debentures SeniorUnsecuredConvertibleDebentures	1130000	usd
CY2023Q4	gthp	Debt Issuance Costs Amortized DebtIssuanceCostsAmortized	-12000	usd
CY2022Q4	gthp	Debt Issuance Costs Amortized DebtIssuanceCostsAmortized	-40000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	38000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	140000	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1080000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	950000	usd
CY2022Q4	gthp	Outstanding Principal Longterm Debt OutstandingPrincipalLongtermDebt	17052	usd
CY2022Q4	gthp	Accrued Interest AccruedInterest	5139	usd
CY2023Q4	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	52752994	shares
CY2022Q4	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	59980134	shares
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3759000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4972000	usd
CY2023	us-gaap	Weighted Average Number Basic Shares Outstanding Adjustment Pro Forma WeightedAverageNumberBasicSharesOutstandingAdjustmentProForma	51131000	shares
CY2022	us-gaap	Weighted Average Number Basic Shares Outstanding Adjustment Pro Forma WeightedAverageNumberBasicSharesOutstandingAdjustmentProForma	32505000	shares
CY2023	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.07
CY2022	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.15
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	51131000	shares
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	32505000	shares
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.07
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.15
CY2023Q4	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards	65500000	usd
CY2017Q4	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards	13100000	usd
CY2023	gthp	Taxable Income Offset TaxableIncomeOffset	0.80	pure
CY2023Q4	gthp	Deferred Tax Assets Warrants DeferredTaxAssetsWarrants	851	usd
CY2022Q4	gthp	Deferred Tax Assets Warrants DeferredTaxAssetsWarrants	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	253000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	259000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	221000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	237000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	237000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	178000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16374000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16390000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17936000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17064000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17936000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17064000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.04	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.04	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.25	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.25	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	872000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-617000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-872000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	617000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	25000	usd
CY2023	gthp	Repayments Of Not Exchange Amount RepaymentsOfNotExchangeAmount	175000	usd
CY2023Q4	gthp	Common Stock Share Issued CommonStockShareIssued	900000	shares
CY2023	gthp	Exercise Price ExercisePrice	0.30

Files In Submission

Name	View Source	Status
0001477932-24-001549-index-headers.html	Edgar Link	pending
0001477932-24-001549-index.html	Edgar Link	pending
0001477932-24-001549.txt	Edgar Link	pending
0001477932-24-001549-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gthp-20231231.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
gthp-20231231_def.xml	Edgar Link	unprocessable
gthp-20231231_lab.xml	Edgar Link	unprocessable
gthp_10k.htm	Edgar Link	pending
gthp_10kimg51.jpg	Edgar Link	pending
gthp_10kimg52.jpg	Edgar Link	pending
gthp_ex231.htm	Edgar Link	pending
gthp_ex31.htm	Edgar Link	pending
gthp_ex321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
gthp_10k_htm.xml	Edgar Link	completed
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
gthp-20231231_cal.xml	Edgar Link	unprocessable
gthp-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GTHP
GUIDED THERAPEUTICS INC Stock $gthp

2024 Q1 Form 10-K Financial Statement

#000147793224001549 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GTHP GUIDED THERAPEUTICS INC Stock $gthp

2024 Q1 Form 10-K Financial Statement

#000147793224001549 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GTHP
GUIDED THERAPEUTICS INC Stock $gthp